About

About Elixiron Immunotherapeutics Inc. Elixiron Immunotherapeutics is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for autoimmune/neurodegenerative diseases and cancer. We employ advances in translational medicine to identify targets from clinical observations, and various drug modalities including biologics, small molecule and mRNA drugs. Our two lead pipeline candidates had completed phase 1 clinical trials. Indemakitug (EI-001), a monoclonal antibody against IFN-g, is being developed for the treatment of vitiligo and other immunological disorders. As a potential first-in-class therapeutic antibody for vitiligo, is on track to start a POC clinical study in vitiligo patients in 2H 2024. Enrupatinib (EI-1071), a small molecule inhibitor of CSF-1R kinase activity, is a two-time winner of Part-the-Cloud awards from Alzheimer's Association. A POC phase II study in Alzheimer's patients will start in 2H 2024. Elixiron Immunotherapeutics is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for autoimmune/neurodegenerative diseases and cancer. We employ advances in translational medicine to identify targets from clinical observations, and various drug modalities including biologics, small molecule and mRNA drugs. Our two lead pipeline candidates had completed phase 1 clinical trials. Indemakitug (EI-001), a monoclonal antibody against IFN-g, is being developed for the treatment of vitiligo and other immunological disorders. As a potential first-in-class therapeutic antibody for vitiligo, is on track to start a POC clinical study in vitiligo patients in 2H 2024. Enrupatinib (EI-1071), a small molecule inhibitor of CSF-1R kinase activity, is a two-time winner of Part-the-Cloud awards from Alzheimer's Association. A POC phase II study in Alzheimer's patients will start in 2H 2024.